

Viewpoint

New insights into the biological function of BRCA2 from its structural interactions

Alison Waterworth

Molecular Medicine Unit, Clinical Sciences Building, St James' University Hospital, Leeds, UK

Corresponding author: Alison Waterworth (e-mail: alisonwaterworth@doctors.org.uk)

Published: 4 February 2003

Breast Cancer Res 2003, **5**:107-108 (DOI 10.1186/bcr581)

© 2003 BioMed Central Ltd (Print ISSN 1465-5411; Online ISSN 1465-542X)

Introduction

Around 50% of all familial breast and ovarian cancers are due to mutations in *BRCA1* and *BRCA2*. Germline mutations in the *BRCA2* gene are associated with an increased susceptibility to breast cancer (in both males and females) and they also confer an increased risk of early onset ovarian, prostate, and pancreatic cancer. The biological function of *BRCA2* in the cell is still uncertain, although there is increasing evidence for a role in the repair of DNA by homologous recombination. *BRCA2* and *RAD51* (a homolog of the bacterial recombination protein *RecA*) both co-localise to nuclear foci thought to be sites of DNA damage and repair and these nuclear foci fail to form in *BRCA2* deficient cells. Loss of *BRCA2* leads to error prone repair of double strand DNA breaks and in dividing cells can lead to chromosomal aberrations and loss of genetic information. Compelling evidence of a more direct role for *BRCA2* in DNA repair is provided by two recent studies investigating some of the protein's structural interactions.

Structural interactions of BRCA2

In an exceptional publication in *Science* [1], Yang and colleagues demonstrate the crystal structure of the 800-residue carboxyl-terminal domain of *BRCA2* that lies beyond the sequence of highly conserved BRC motifs (sets of amino acid repeats in the centre of *BRCA2*). This carboxyl-terminal region is likely to play an important role in the tumour suppressor function of *BRCA2* as it corresponds to the most conserved portion of *BRCA2* across different species and contains 27% of tumour-derived missense mutations. The authors strengthen this hypothesis by presenting the 3.1 angstrom structure of the carboxyl-terminal domain bound to another protein, DSS1 (deleted in split hand/split foot syndrome), and show that this structure contains multiple areas similar to single stranded and double stranded DNA binding motifs. They also show that this domain of *BRCA2* can bind to single stranded DNA and stimulate *RAD51* mediated recombination *in vitro*. Their data thus indicate a direct role for

BRCA2 in homologous recombination and provide a structural insight into the loss of recombination mediated DNA repair in *BRCA2* associated cancers.

Pellegrini and colleagues from Cambridge University explore further the structural interactions between *BRCA2* and *RAD51* and their role in DNA repair [2]. This paper reports for the first time the crystal structure of the complex between a BRC repeat and the catalytic domain of *RAD51*. The BRC repeat is found to mimic a motif in *RAD51* that serves as an interface between adjacent *RAD51* monomers. Through molecular mimicry, *BRCA2* may therefore control the formation of the *RAD51* nucleoprotein filament, which is essential for DNA recombination. This provides a structural basis for the *BRCA2* regulation of *RAD51* function and explains how *BRCA2* mutations may disrupt the predicted interactions between BRC and *RAD51* and cause increased cancer susceptibility.

Conclusion

Both studies outlined demonstrate the importance of structural analyses to further knowledge of protein function. They provide direct evidence for the role of *BRCA2* in DNA repair and also a structural basis for the loss of recombination-mediated double strand DNA break repair in *BRCA2*-associated cancers. The challenge now is to take advantage of this deficiency in homologous recombination to specifically target and destroy *BRCA2* mutant cells in cancer patients.

Competing interests

None declared.

References

1. Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, Thoma NH, Zheng N, Chen PL, Lee WH, Pavletich NP: **BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.** *Science* 2002, **297**:1837-1848.
2. Pellegrini L, Yu DS, Lo T, Anand S, Lee M, Blundell TL, Venkitaraman AR: **Insights into DNA recombination from the structure of a RAD51-BRCA2 complex.** *Nature* 2002, **420**: 287-293.

Note

This article is based on papers highlighted by Faculty of 1000 (<http://www.facultyof1000.com/start.asp>), a web-based literature awareness service. Faculty of 1000 evaluations available for articles cited in this report may be viewed at: <http://breast-cancer-research.com/reports/bcr581.asp>

Correspondence

Alison Waterworth, Molecular Medicine Unit, Clinical Sciences Building, St James' University Hospital, Leeds LS9 7TF, UK. Tel: +44 (0)113 206 6655; fax: +44 (0)113 244 4475; e-mail: alisonwaterworth@doctors.org.uk